Cargando…

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients

According to a recent World Health Organization estimate, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, which originated in China in 2019, has spread globally, infecting nearly 100 million people worldwide by January 2021. Patients with chronic liver diseases (CLD), part...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornberg, Markus, Buti, Maria, Eberhardt, Christiane S., Grossi, Paolo Antonio, Shouval, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Association for the Study of the Liver. Published by Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867401/
https://www.ncbi.nlm.nih.gov/pubmed/33563499
http://dx.doi.org/10.1016/j.jhep.2021.01.032
_version_ 1783648294354812928
author Cornberg, Markus
Buti, Maria
Eberhardt, Christiane S.
Grossi, Paolo Antonio
Shouval, Daniel
author_facet Cornberg, Markus
Buti, Maria
Eberhardt, Christiane S.
Grossi, Paolo Antonio
Shouval, Daniel
author_sort Cornberg, Markus
collection PubMed
description According to a recent World Health Organization estimate, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, which originated in China in 2019, has spread globally, infecting nearly 100 million people worldwide by January 2021. Patients with chronic liver diseases (CLD), particularly cirrhosis, hepatobiliary malignancies, candidates for liver transplantation, and immunosuppressed individuals after liver transplantation appear to be at increased risk of infections in general, which in turn translates into increased mortality. This is also the case for SARS-CoV-2 infection, where patients with cirrhosis, in particular, are at high risk of a severe COVID-19 course. Therefore, vaccination against various pathogens including SARS-CoV-2, administered as early as possible in patients with CLD, is an important protective measure. However, due to impaired immune responses in these patients, the immediate and long-term protective response through immunisation may be incomplete. The current SARS-CoV-2 pandemic has led to the exceptionally fast development of several vaccine candidates. A small number of these SARS-CoV-2 vaccine candidates have already undergone phase III, placebo-controlled, clinical trials in healthy individuals with proof of short-term safety, immunogenicity and efficacy. However, although regulatory agencies in the US and Europe have already approved some of these vaccines for clinical use, information on immunogenicity, duration of protection and long-term safety in patients with CLD, cirrhosis, hepatobiliary cancer and liver transplant recipients has yet to be generated. This review summarises the data on vaccine safety, immunogenicity, and efficacy in this patient population in general and discusses the implications of this knowledge on the introduction of the new SARS-CoV-2 vaccines.
format Online
Article
Text
id pubmed-7867401
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Association for the Study of the Liver. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-78674012021-02-09 EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients Cornberg, Markus Buti, Maria Eberhardt, Christiane S. Grossi, Paolo Antonio Shouval, Daniel J Hepatol Position Paper According to a recent World Health Organization estimate, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, which originated in China in 2019, has spread globally, infecting nearly 100 million people worldwide by January 2021. Patients with chronic liver diseases (CLD), particularly cirrhosis, hepatobiliary malignancies, candidates for liver transplantation, and immunosuppressed individuals after liver transplantation appear to be at increased risk of infections in general, which in turn translates into increased mortality. This is also the case for SARS-CoV-2 infection, where patients with cirrhosis, in particular, are at high risk of a severe COVID-19 course. Therefore, vaccination against various pathogens including SARS-CoV-2, administered as early as possible in patients with CLD, is an important protective measure. However, due to impaired immune responses in these patients, the immediate and long-term protective response through immunisation may be incomplete. The current SARS-CoV-2 pandemic has led to the exceptionally fast development of several vaccine candidates. A small number of these SARS-CoV-2 vaccine candidates have already undergone phase III, placebo-controlled, clinical trials in healthy individuals with proof of short-term safety, immunogenicity and efficacy. However, although regulatory agencies in the US and Europe have already approved some of these vaccines for clinical use, information on immunogenicity, duration of protection and long-term safety in patients with CLD, cirrhosis, hepatobiliary cancer and liver transplant recipients has yet to be generated. This review summarises the data on vaccine safety, immunogenicity, and efficacy in this patient population in general and discusses the implications of this knowledge on the introduction of the new SARS-CoV-2 vaccines. European Association for the Study of the Liver. Published by Elsevier B.V. 2021-04 2021-02-06 /pmc/articles/PMC7867401/ /pubmed/33563499 http://dx.doi.org/10.1016/j.jhep.2021.01.032 Text en © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Position Paper
Cornberg, Markus
Buti, Maria
Eberhardt, Christiane S.
Grossi, Paolo Antonio
Shouval, Daniel
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients
title EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients
title_full EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients
title_fullStr EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients
title_full_unstemmed EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients
title_short EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients
title_sort easl position paper on the use of covid-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients
topic Position Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867401/
https://www.ncbi.nlm.nih.gov/pubmed/33563499
http://dx.doi.org/10.1016/j.jhep.2021.01.032
work_keys_str_mv AT cornbergmarkus easlpositionpaperontheuseofcovid19vaccinesinpatientswithchronicliverdiseaseshepatobiliarycancerandlivertransplantrecipients
AT butimaria easlpositionpaperontheuseofcovid19vaccinesinpatientswithchronicliverdiseaseshepatobiliarycancerandlivertransplantrecipients
AT eberhardtchristianes easlpositionpaperontheuseofcovid19vaccinesinpatientswithchronicliverdiseaseshepatobiliarycancerandlivertransplantrecipients
AT grossipaoloantonio easlpositionpaperontheuseofcovid19vaccinesinpatientswithchronicliverdiseaseshepatobiliarycancerandlivertransplantrecipients
AT shouvaldaniel easlpositionpaperontheuseofcovid19vaccinesinpatientswithchronicliverdiseaseshepatobiliarycancerandlivertransplantrecipients